Stockwatch: Riding the M&A rollercoaster
This article was originally published in Scrip
An important dynamic currently driving the biopharmaceutical space is the replacement of lost product revenue at pharmaceutical companies through merger and acquisition (M&A) transactions biotechs with promising pipelines. However, the hoped for renewal is not always a smooth path and is more often more akin to riding a rollercoaster.
You may also be interested in...
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.